Literature DB >> 11270408

Cryptococcosis in India: the awakening of a giant?

U Banerjee1, K Datta, T Majumdar, K Gupta.   

Abstract

The menace of cryptococcosis has assumed global proportions over the years. The tropical climate of the Indian subcontinent offers a suitable environment for Cryptococcus neoformans, and the onslaught of the acquired immune deficiency syndrome (AIDS) pandemic since the early 1990s has substantially influenced the situation. Coupled with that are the advances in laboratory diagnostic techniques that have made accurate diagnosis increasingly available. These factors together have led to a sharp increase in the number of reported cases of cryptococcosis. This review attempts to present an overview of the status of cryptococcosis in India from its first description to the most recent times. The disease has been reported from almost all parts of the country. C. neoformans var. neoformans is predominantly found in clinical samples, while C. n. var. gattii infection has also been reported. An organ commonly involved is the central nervous system, among others. Both immunocompromised and apparently immunocompetent patients have been affected. Laboratory diagnosis is mostly by conventional methods, while effective therapeutic options are limited. Early diagnosis followed by institution of specific therapy, where possible, has effectively reduced mortality. Awareness of the disease and maintenance of a high index of clinical suspicion is required. An integrated approach to patient management with active interaction between the clinicians and the laboratory personnel would be highly beneficial. The wide variety of presentations of the disease seen in India suggests the possibility of occurrence of strain variation which needs to be investigated fully. Introduction of routine testing of antifungal susceptibility of clinical isolates is also important in order to obtain baseline data on susceptibility patterns and to predict in advance any shift in those patterns in the population. To maintain a high standard in all such endeavours, the establishment of an external quality control system is desirable.

Entities:  

Mesh:

Year:  2001        PMID: 11270408     DOI: 10.1080/mmy.39.1.51.67

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  21 in total

1.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

2.  Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.

Authors:  Dolan Champa Saha; Immaculata Xess; Wang Yong Zeng; David L Goldman
Journal:  Med Mycol       Date:  2008-03-10       Impact factor: 4.076

3.  Molecular epidemiology of clinical Cryptococcus neoformans strains from India.

Authors:  N Jain; B L Wickes; S M Keller; J Fu; A Casadevall; P Jain; M A Ragan; U Banerjee; B C Fries
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Dual infections with pigmented and albino strains of Cryptococcus neoformans in patients with or without human immunodeficiency virus infection in India.

Authors:  Piyali Mandal; Uma Banerjee; Arturo Casadevall; Joshua D Nosanchuk
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans.

Authors:  Krishanthi Subramaniam; Neil French; Liise-Anne Pirofski
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

Review 6.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Three galactose inducible promoters for use in C. neoformans var. grubii.

Authors:  Jack A Ruff; Jennifer K Lodge; Lorina G Baker
Journal:  Fungal Genet Biol       Date:  2008-10-14       Impact factor: 3.495

9.  Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.

Authors:  Kausik Datta; Andrew Lees; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

10.  Cryptococcus gattii: Emergence in Western North America: Exploitation of a Novel Ecological Niche.

Authors:  Kausik Datta; Karen H Bartlett; Kieren A Marr
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.